Compare Gen Digital Inc. Common Stock (GEN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gen Digital Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gen Digital Inc. Common Stock trades at $23.77 (market cap $14.24B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Gen Digital Inc. Common Stock is far larger — about 14.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Gen Digital Inc. Common Stock pays a 2.1% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gen Digital Inc. Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GEN | MRVI | |
|---|---|---|
Market Cap | $14.24B | $972.90M |
Volume | 6,202,699 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $31.41 | $9.00 |
52-Week Low | $17.89 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $21.89B | $1.08B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEN Digital Inc. (GEN) trades at $23.81, up 1.97% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 13.92, net income margin of 20.73%, and robust cash flow from operations of $1.22B in 2025. Recent news highlights include a takeover bid for GoDaddy and participation in investor conferences, reflecting strategic moves in the cybersecurity and digital services sector.
The outlook is mixed: analyst consensus targets $25.50 with a balanced buy/hold split, but technical indicators suggest near-term pressure. Key risks include high debt levels and integration challenges from acquisitions. Earnings growth and market expansion into AI services present opportunities, though volatility may persist amid competitive and macroeconomic headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gen Digital Inc. Common Stock
Gen Digital provides cybersecurity, online privacy, identity protection, and financial wellness services. Its consumer brands include Norton, Avast, LifeLock, and MoneyLion.
Read more on GEN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
